Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 programMELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex ...

Over the past decade, the economics of drug development have become increasingly unforgiving. Global pharmaceutical R&D spending now exceeds $300 billion annually, yet bringing a new therapy to market ...

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, ...

This finding is pivotal for the company’s development strategy, as it suggests that patient selection based on CD47 expression could significantly improve clinical outcomes. ALX Oncology is applying ...

Understand the impact of IND delays on biotechnology companies and how they affect early-stage development and funding.

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...

Company reports encouraging monotherapy expansion data in platinum-resistant ovarian cancer and initiates first combination study with standard-of-care chemotherapies in Q1 2026 Timothy Bowler, M.D., ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NNVC) (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that ...